PMID: 12820313Jun 25, 2003Paper

Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening

Anticancer Research
P D HardtH U Kloer

Abstract

Recently we were able to demonstrate that Tumor M2 Pyruvate Kinase (Tumor M2-PK) is detectable in the feces of patients with gastrointestinal (GI) cancer. In this study an ELISA based on a different combination of antibodies was used to investigate stool samples of GI cancer patients. The ELISA (ScheBoBiotech AG, Giessen, Germany) was based on one antibody specific for Tumor M2-PK and a second antibody reacting with Tumor M2-PK, M1-PK and the tetrameric M2-PK. Stool samples of healthy controls, patients with inflammatory bowel disease (IBD) and different kinds of GI cancer were tested. Compared to controls, samples of IBD or different tumors did not show significant differences, except those patients with gastric cancer (elevated fecal PK in 80% (p = 0.005)). If the present results can be confirmed in larger patient samples, this new test might provide an excellent screening tool for gastric cancer.

Related Concepts

Monoclonal Antibodies
Antibody Specificity
Differential Diagnosis
Enzyme-Linked Immunosorbent Assay
Feces
R-Type Pyruvate Kinase
Hereditary Diffuse Gastric Cancer
Tumor Markers
Colorectal Neoplasms
Inflammatory Bowel Diseases

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.